Yeast cell-wall (MOS/β-glucan), nucleotide and postbiotic additives instead of the antibiotic-growth-promoter era's ingredient logic

Replaces: AGP-era additive logic (with V01) · Scope: young-animal, aqua, pet feeds · Evidence: medium–high

The chemical problem#

• When antibiotic growth promoters left (EU 2006; China 2020 colistin; V01’s timeline), the feed industry had a hole where a cheap “performance insurance” used to sit.
• The lazy replacements were like-for-like chemicals — and high-dose pharmacological zinc/copper, which co-select AMR and load soils — the same problem wearing a new vest.
• What the biology actually offers is not one substitute molecule but a program: gut architecture, microbiome steering and immune readiness (V-series pattern).

Product overview#

1. Yeast cell-wall fractions: mannan-oligosaccharides (MOS) block pathogen fimbriae binding; β-(1,3/1,6)-glucans prime innate immunity — both from Saccharomyces brewery/ alcohol streams (a true by-product valorization).
2. Yeast nucleotides: RNA fractions for rapidly turning gut tissue — prestarter piglet/chick and aqua-fry diets (growth without drugs).
3. Postbiotics: inactivated yeast and fermentation metabolites (the V01 probiotic concept without live-cell handling).
4. Program context: works as part of the V01/FD01 stack (enzymes, acids, vaccines, hygiene), not instead of it.

Active ingredient / Composition#

• MOS/β-glucan powders standardized to mannose/glucan fractions; nucleotide products ≥5 % RNA-equivalent; dosing 0.5–2 kg/t in prestarter/aqua.

Key facts#

• | Evidence shape | Consistent small-to-moderate effects; best in challenge/young-animal windows |

Advantages#

• Fills the post-AGP shelf with by-product-derived ingredients (brewer’s yeast, ethanol yeast) — circular and cheap at source.
• No residues, no withdrawal, no AMR load — export-compliant by construction.
• Pairs with FD02 insect meals and FD01 enzymes in the same reformulation exercise.

Mode of action#

• MOS mimics mannose-rich gut receptors: type-1 fimbriated E. coli/Salmonella bind the feed particle instead of the enterocyte → pass out.
• β-glucans interact with dendritic/Peyer’s-patch receptors (dectin-1 class) tuning innate readiness.
• Nucleotides spare de-novo synthesis in fast-turnover gut tissue during weaning/hatch stress.

Application#

Limitations#

• Honest rating: Partial. Effects are context-dependent (challenge level, base diet, hygiene); these are program components, not magic.
• Quality variance between yeast streams; standardized fractions cost more.
• Not a substitute for vaccines, hygiene or FD01 precision when those are the gap.

Evidence of displacement — D2: measurable displacement (minority share)#

Assessment (hand-reviewed): US medically important antibiotic sales down 38% after the ban (2015–2021) — the old practice fell; the postbiotics’ share is not shown.

Figures found (verified as quoted, but the assessment above explains why they do not count as displacement evidence for this substitution):

• displacement — In the United States, there was a 38% decrease in the marketed volume of antibiotics for livestock in 2021 compared to peak sales in 2015. (United States, 2015-2021; peer-reviewed: frontiersin.org)
• displacement — Feed mills in Germany and the Netherlands have increased organic trace mineral inclusion by 15-20% since 2024 as part of a shift toward alternatives following the EU ban on antibiotic growth promoters. (Germany and the Netherlands, since 2024; weak: mordorintelligence.com)
• displacement — In 2022, 71% of WOAH Members reported that the use of antimicrobial agents for growth promotion is no longer authorised. (global, 2022; weak: woah.org)
• displacement — In Belgium, the total reduction in sales of antibacterial premixes for veterinary use between 2011 and 2024 reached 89.1%. (Belgium, 2011-2024; weak: fagg-afmps.be)

Suppliers — real products and services (from the vendor index)#

Active vendors matched by topic tags (yeast-fermentation-ingredients, probiotics-dairy-cultures, feed-additives); open each card for evidence, contacts and status.

Government funding signals#

Scanned 2026-09-28 (OpenAIRE + NSF); candidates reviewed by hand.

Signal: none — ingredient-industry territory. Yeast-fraction R&D is funded inside the animal-nutrition industry (supplier trials, university contract work) rather than open research grants; compare V01 (Strong, via the AMR public-health route) for where the adjacent public money actually sits.

Scientific evidence#

• Note: this article intentionally leans on the V01/V02 stack for the AGP-era evidence; the yeast-fraction literature is broad but effect-heterogeneous. A targeted evidence list will be added after the Crossref pass selects checkable anchors.

Bioeconomy value#

The AGP shelf gets refilled by brewery residue: yeast walls, nucleotides and postbiotics from beer and ethanol streams (EN02’s mills) — the circular feedstock answer to a drug-shaped hole.

Fifth article of feed — completes the collection’s planned set. Cross-links: V01/V02 (the AGP exit), FD01 precision, FD02 protein, FD03 acids; yeast streams ↔ FI04/EN02.